In the dynamic landscape of healthcare innovation, few companies stand out as champions of change. As a venture capital firm deeply committed to addressing the rising costs of healthcare, we’re thrilled to announce our continued investment in VenoStent. The stellar results from their feasibility study, their unwavering focus on clinical excellence and milestone execution, andContinue reading “Why we invested in VenoStent…again”
Author Archives: Kulika Weizman
Cutting through the hype of AI drug discovery
In the world of AI and biotechnology, everyone seems to be shouting, “drug discovery is the next big thing!” Do yourself a favor, and don’t get swept away by the hype train just yet. Teasing out those who are tackling critical challenges with plausible paths to market from ones that may be suited for therapeutic-focusedContinue reading “Cutting through the hype of AI drug discovery”
3 key takeaways from the 2023 SynBioBeta Conference
3 key takeaways from the 2023 SynBioBeta conference in Oakland, CA.
Why we invested in 3E Nano
We’re thrilled to welcome 3E Nano to our portfolio.
3 Takeaways from the 2023 JP Morgan Healthcare Conference
Principal Kulika reflects on the in-person conference, her panels, and more.
Reflecting on BioFuture & value-based care
Principal Kulika’s reflections on BioFuture and whether the value-based care model is investible.
The do’s and dont’s of sharing proprietary information
VC’s want to invest in companies, not rebuild or downright copy what you are doing. If you have done your diligence and everything checks out, withholding too much information will raise some red flags.
Diversity in clinical trials: necessary but insufficient
Higher drug approval rates, lower clinical trial costs, and improved efficacy are within reach with the right tools.
Tapping into the power of nature
Despite and because of all the challenges lined up between bench-top and commercialization, it is critical to take a market-driven approach when picking a synthetic biology product.
The importance of empirical evidence for early-stage deeptech companies
Here are three must-have sections for when you’re compiling your empirical evidence: